ABOUT US

Introduction
Chairman's Statement
Contact Us
R&D

R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS

bFGF Series
other ophthalmic products
other surgical products
NEWS

company news
investee news
media focus
INVESTOR RELATIONS

Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS

Talent Concept
Job Opportunities
简 繁 EN
Essex-Bio Group
简 繁 EN
简 繁 EN
COMPANY NEWS
Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC
2022.05.07
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting
2022.04.29
Time
Last 7 days Last 30 days The last six months
Date
Title
2021-08-12
Essex Bio-Technology Reports First Half 2021 Financial Results
2021-07-25
Essex Bio-Technology Listed on Two Authoritative Lists
2021-07-19
First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-04-30
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting
2021-04-20
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-07
Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercilisation in China
2021-03-19
Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD
2021-03-12
Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half
 1 2 3 4 5 6 
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Contact us
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy
粤公网安备 44049102496184号粤ICP备09032349号-1 深圳网站建设 深圳联雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT